ResearcherSecond Hospital of Shandong UniversityNo recent work listed

Hongbo Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8530-2339; OpenAlex author ID A5100395748. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper

Papers 2

Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer? Co-author DOI 10.1016/j.jconrel.2019.05.018 ↗
LncRNA ADPGK-AS1 promotes pancreatic cancer progression through activating ZEB1-mediated epithelial-mesenchymal transition. Last author DOI 10.1080/15384047.2018.1423912 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Zimei Wu · 1 shared paper, 2019 · strength 0.11
- Paper Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resist… DOI 10.1016/j.jconrel.2019.05.018 ↗
Mingtan Tang · 1 shared paper, 2019 · strength 0.11
- Paper Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resist… DOI 10.1016/j.jconrel.2019.05.018 ↗
Suzhen Song · 1 shared paper, 2018 · strength 0.09
- Paper LncRNA ADPGK-AS1 promotes pancreatic cancer progression through activating ZEB1-mediated epithelial-mesenchymal transit… DOI 10.1080/15384047.2018.1423912 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.